JPMorgan analyst Calvin Sternick lowered the firm’s price target on Molina Healthcare to $420 from $435 and keeps an Overweight rating on the shares. The firm believes diversified managed care organizations and hospitals remain best positioned within its large cap coverage universe. Within managed care, a more defensive approach is still the best way to play the group over the near-term, the analyst tells investors in a research note. JPMorgan remains more cautious on Medicare Advantage given lack of visibility on 2024 cost trends and uncertainty around 2025 bids.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MOH:
- Molina Healthcare of Wisconsin receives NoI to award Region 5 contract
- Molina Healthcare price target lowered to $412 from $453 at TD Cowen
- Molina Healthcare price target lowered to $375 from $410 at Wells Fargo
- Molina Healthcare price target lowered to $430 from $437 at Barclays
- Molina Healthcare reports Q1 Medical Care Ratio 88.5%